Relay Therapeutics Inc

RLAY is in a Stage 2 advancing uptrend with sustained demand via Devil’s Bargain continuation pattern, but with extreme overbought readings and flattening EMAs, short-term timing is unfavorable. Execution should be deferred until a shallow pullback into the 9EMA/21EMA zone shows signs of acceptance and continuation. Key risks include a deeper retracement below EMAs or a failure at overhead resistance, which could signal a shift toward Stage 3.

• ↑60% volumetric response at 12 weeks for zovegalisib in Phase 2 ReInspire trial
• ↑Raised $275 M in public offering to fund trials and R&D
• ↓Severely negative profit margins highlight challenges in achieving profitability